FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma?utm_campaign=Oncology%207-31-2020%20atezolizumab&utm_medium=email&utm_source=Eloqua&elqTrackId=38552F7B5C55F017B66C6336EE62E571&elq=27e33b70465a4022b796ba5a339e2001&elqaid=13603&elqat=1&elqCampaignId=11643

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma

Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. More Information. July 30, 2020.